Search Within

Young Rock Chung

Formats
  1. Meeting Abstract (25)
  2. Journal Article (23)
Groups
  1. Center for Hematologic Malignancies (47)
  2. Department of Medicine (47)
  3. Executive Committee, Center for Hematologic Malignancies (47)
  4. GSK Faculty (47)
  5. Hematologic Malignancies, Division of (47)
  6. Tow Center for Developmental Oncology (TCDO) (47)

More Groups

People
  1. Omar Abdel-Wahab (47)
  2. Eunhee Kim (19)
  3. Benjamin Durham (18)
  4. Ross Levine (14)
  5. Jae Park (13)
  6. Stanley Lee (13)

More People

Years
  1. 2023 (1)
  2. 2019 (1)
  3. 2018 (3)
  4. 2017 (10)
  5. 2016 (4)
  6. 2015 (9)

More Years

Publications
  1. Blood (20)
  2. Nature Medicine (3)
  3. Cancer Cell (2)
  4. Cancer Research (2)
  5. New England Journal of Medicine (2)
  6. Science Translational Medicine (2)

More Publications

Publishers
  1. American Society of Hematology (21)
  2. Nature Publishing Group (6)
  3. American Association for Cancer Research (4)
  4. Cell Press (3)
  5. American Association for the Advancement of Science (2)
  6. Massachusetts Medical Society (2)

More Publishers

Results (48)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Therapeutic targeting of spliceosomal mutant myeloid leukemias through modulation of splicing catalysis
    Meeting Abstract

    Lee, S. C. W.; Dvinge, H.; Kim, E.; Cho, H. N.; Chung, Y. R.; Micol, J. B.; Durham, B.; Kim, Y. J.; Thomas, M.; Lobry, C.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • ASXL2 is a novel mediator of RUNX1-ETO transcriptional function and collaborates with RUNX1-ETO to promote leukemogenesis
    Meeting Abstract

    Micol, J. B.; Duployez, N.; Pastore, A.; Williams, R.; Kim, E.; Lee, S.; Durham, B.; Chung, Y. R.; Cho, H. N.; Preudhomme, C.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia
    Journal Article

    Tiacci, E.; Park, J. H.; De Carolis, L.; Chung, S. S.; Broccoli, A.; Scott, S.; Zaja, F.; Devlin, S.; Pulsoni, A.; Chung, Y. R.; more...
    New England Journal of Medicine (2015)

    Fulltext@MSK | Save
  • Loss of BAP1 function leads to EZH2-dependent transformation
    Journal Article

    LaFave, L. M.; Béguelin, W.; Koche, R.; Teater, M.; Spitzer, B.; Chramiec, A.; Papalexi, E.; Keller, M. D.; Hricik, T.; Konstantinoff, K.; more...
    Nature Medicine (2015)

    Fulltext@MSK | Save
  • SRSF2 mutations impair hematopoietic differentiation by altering exonic splicing enhancer preference
    Meeting Abstract

    Kim, E.; Ilagan, J. O.; Lee, S.; Ramakrishnan, A.; Chung, Y. R.; Micol, J. B.; Murphy, M. E.; Kim, M. K.; Zebari, A. S.; Buonamici, S.; more...
    Clinical Cancer Research (2015)

    Fulltext@MSK | Save
  • Diverse kinase mutations and fusions drive non-Langerhans cell histiocytoses
    Meeting Abstract

    Durham, B.; Diamond, E.; Yao, Z.; Ma, J.; Choi, J.; Kim, E.; Lee, S.; Gao, Y.; Micol, J. B.; Campbell, P.; more...
    Pediatric Blood and Cancer (2015)

    Fulltext@MSK | Save
  • SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition
    Journal Article

    Kim, E.; Ilagan, J. O.; Liang, Y.; Daubner, G. M.; Lee, S. C. W.; Ramakrishnan, A.; Li, Y.; Chung, Y. R.; Micol, J. B.; Murphy, M. E.; more...
    Cancer Cell (2015)

    Fulltext@MSK | Save
  • Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders
    Journal Article

    Hyman, D. M.; Diamond, E. L.; Vibat, C. R. T.; Hassaine, L.; Poole, J. C.; Patel, M.; Holley, V. R.; Cabrilo, G.; Lu, T. T.; Arcila, M. E.; more...
    Cancer Discovery (2015)

    Fulltext@MSK | Save
  • Context specific effects of the BRAFV600E mutation on hematopoiesis identifies novel models of BRAF mutant hematopoietic disorders
    Meeting Abstract

    Kim, E.; Chung, S. S.; Park, J. H.; Chung, Y. R.; Lito, P.; Feldstein, J.; Hu, W. H.; Beguilin, W.; Monette, S.; Duy, C.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Vemurafenib has potent antitumor activity in patients with relapsed/refractory BRAF mutant hairy cell leukemia
    Meeting Abstract

    Park, J. H.; Chung, S. S.; Chung, Y. R.; Won, H.; Kim, E.; Saven, A.; Wadleigh, M.; Stone, R. M.; Barrientos, J. C.; Rai, K. R.; more...
    Blood (2014)

    Fulltext@MSK | Save